
- 2 in severe COVID-19
- 3 Abhimanyu Chandel¹¶*, Saloni Patolia²¶, Mary Looby³¶, Heidi J. Dalton^{4&} Najeebah Bade^{5&},
- 4 Vikramjit Khangoora^{6&}, Mehul Desai^{7&}, James Lantry^{7&}, Erik Osborn^{7&}, Svetolik Djurkovic^{7&},
- 5 Daniel Tang^{8&}, Steven D. Nathan6[&], Christopher S. King^{6¶}
- ¹Department of Pulmonology and Critical Care, Walter Reed National Military Medical Center,
- 8 Bethesda, MD, USA

6

- ²Virginia Commonwealth University School of Medicine, Richmond, VA, USA
- ³Department of Pharmacy, Inova Fairfax Hospital, Falls Church, VA, USA
- ⁴Heart and Vascular Institute, Inova Fairfax Hospital, Falls Church, VA, USA
- ⁵Department of Hematology, Inova Fairfax Hospital, Falls Church, VA, USA
- ⁶Department of Advanced Lung Disease and Transplant, Inova Fairfax Hospital, Falls Church,
- 14 VA, USA

17

- ⁷Department of Medical Critical Care, Inova Fairfax Hospital, Falls Church, VA, USA
- ⁸Department of Cardiothoracic Surgery, Inova Fairfax Hospital, Falls Church, VA, USA
- * Corresponding Author
- 19 E-mail: Abhimanyu.chandel.mil@mail.mil (AC)



Abstract

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

Introduction: D-dimer concentration has been used to identify candidates for intensified anticoagulant treatment for both venous thromboembolism prevention and mitigation of the microthrombotic complications associated with COVID-19. Thromboelastography (TEG) maximum amplitude (MA) has been validated as an indicator of hypercoagulability and $MA \ge 68$ mm has been utilized as a marker of hypercoagulability in other conditions. We evaluated the relationship between coagulation, inflammatory, and TEG parameters in patients with COVID-19 on extracorporeal membrane oxygenation (ECMO). **Methods:** We performed a single center retrospective analysis of consecutive patients that received ECMO for the treatment of COVID-19. TEG, inflammatory, and coagulation markers were compared in patients with and without thrombotic complications. Correlation tests were performed to identify the coagulation and inflammatory markers that best predict hypercoagulability as defined by an elevated TEG MA. **Results:** 168 TEGs were available in 24 patients. C-reactive protein and fibringen were significantly higher in patients that developed a thrombotic event versus those that did not (p=0.038 and p=0.043 respectively). D-dimer was negatively correlated with TEG MA (p<0.001) while fibringen was positively correlated (p<0.001). A fibringen > 441 mg/dL had a sensitivity of 91.2% and specificity of 85.7% for the detection of MA \geq 68 mm. **Conclusions:** In critically ill patients with COVID-19, D-dimer concentration had an inverse relationship with hypercoagulability as measured by TEG MA. D-dimer elevation may reflect severity of COVID-19 related sepsis rather than designate patients likely to benefit from

anticoagulation. Fibrinogen concentration may represent a more useful marker of hypercoagulability in this population.

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

Critically ill coronavirus disease 2019 (COVID-19) patients have been noted to display features of hypercoagulopathy involving both microthrombosis and macrothrombotic events. These patients have frequently been observed to have significant laboratory abnormalities that are compatible with a hypercoagulable state including severe derangements of D-dimer, fibringen, and thromboelastography (TEG) parameters.[1, 2] Thrombosis, including venous thromboembolism (VTE), arterial thrombosis, and microthrombosis, is thought to be a sequelae of the pathogenesis of severe COVID-19 infection. Autopsies of COVID-19 infected patients have demonstrated the presence of pulmonary microthrombi and it has been postulated that microthrombus formation may contribute to endorgan dysfunction and failure.[3-5] One approach to the management of critically ill COVID-19 patients has been the use of therapeutic anticoagulation to mitigate this hypercoagulability. Multiple local and regional organizations have advocated for the use of D-dimer testing and threshold values as a means to guide the intensity of anticoagulant therapy. [6, 7] This practice is based in part on observational evidence suggesting that treatment of patients with COVID-19 with anticoagulation is associated with improved in-hospital survival.[8] Additionally, the magnitude of D-dimer elevation independently correlates to risk of VTE in general medical patients, and furthermore, correlates to mortality in COVID-19.[9, 10] However, D-dimer is a non-specific marker that is produced as the result of fibrin formation and degradation as a downstream product of thrombin cleavage of fibrinogen.[11] Although elevated D-dimer levels are observed with the presence of VTE, D-dimer is non-specific and often

markedly elevated in other conditions including sepsis in the absence of clinically evident VTE.[12] It is not clear that the magnitude of D-dimer elevation in COVID-19 correlates with hypercoagulability or clinical conditions that are likely to benefit from anticoagulation.[2] It is also not clear that D-dimer represents a superior marker for hypercoagulability over other available tests of the coagulation system or inflammatory markers including fibrinogen, ferritin, and C-reactive protein (CRP). TEG maximum amplitude (MA), a measure of clot strength accounting for platelet and fibrin contributions, has been validated as a marker of hypercoagulability in a wide range of conditions and has been found to correlate with macrothrombotic events.[13] Previous studies have defined hypercoagulability by a TEG MA ≥ 68 mm.[14] In this study we evaluated the relationship between commonly utilized laboratory parameters and hypercoagulability as represented by TEG MA.

Methods

We performed a retrospective medical record review of consecutive hospitalized patients admitted to Inova Fairfax Hospital, a tertiary care referral center in Falls Church, Virginia, USA between March 5, 2020 and May 29, 2020 with a diagnosis of COVID-19 confirmed by positive PCR testing and undergoing extracorporeal membrane oxygenation (ECMO). The study was approved by the Institutional Review Board (IRB# 18-3317) at Inova Fairfax Hospital.

Only patients on ECMO were evaluated as it is standard practice at our institution to obtain daily TEGs as part of the routine care of these patients. TEG was performed using the TEG 5000 platform (Haemonetics Corporation, Braintree, MA). TEGs were conducted using citrated whole blood, kaolin activator, and heparinase for patients on heparin. D-dimer values are reported by our laboratory in ug/mL of fibrinogen equivalent units (FEU).

Data was abstracted in a structured format by one of the authors (SP) and entered into a customized data form. Data was collected when available for standard TEG parameters (R-time and MA), D-dimer, fibrinogen, CRP, and ferritin. D-dimer values > 20 ug/mL FEU were recorded as 20 ug/mL FEU and R-time reported as > 60 min was denoted as 60 min. TEG and inflammatory markers or coagulation studies were compared if drawn within 24 hours. For patients on systemic heparin, TEG parameters with the use of heparin neutralization were collected. Demographic data, anticoagulant usage, and clinical outcomes including bleeding, macrothrombotic complications, and time on ECMO were recorded. Diagnosis of a macrothrombotic event (deep vein thrombosis, pulmonary embolism, or other large vessel venous or arterial blood clot) was recorded based on radiographic report finalized during hospitalization or point-of-care ultrasound findings consistent with VTE in patients with acute decompensation and suspected pulmonary embolism. Bleeding was defined as a clinically observed event, as reported by the treating clinician, that necessitated transfusion of red blood cells.

Statistical Analysis

Distribution of all continuous data was examined for normality using visual inspection and the Wilk Shapiro test. Laboratory characteristics of the groups are presented as the median and interquartile range and compared using the Wilcoxon rank sum test. Categorical data are presented as counts with proportions and compared using Fisher's exact test (two-tailed). A p value < 0.05 was considered statistically significant.

MA, fibrinogen, and CRP had skewed distributions. To reduce the impact of outliers and for parametric modeling, the natural log of these variables is used in graphical presentations and

Results

Twenty-four consecutive patients with COVID-19 requiring ECMO support were included in the final cohort. Patients were grouped by the presence or absence of diagnosed macrothrombosis during hospitalization. Twelve patients developed macrothrombosis either while receiving ECMO or after this therapy was discontinued (9 deep vein thromboses, 2 pulmonary emboli, and one episode of embolic mesenteric ischemia). Two patients developed bleeding complications (hemoptysis and gastrointestinal hemorrhage). Demographic data, laboratory values, and clinical outcomes between groups are displayed in Table 1. Patients with imaging confirmed macrothrombosis were significantly more likely to have higher median CRP and fibrinogen values.

hospitalization

167

168

169 170

171

172

173

174

175

176

177

178

	All Subjects	Macrothrombosis	No thrombosis	P Value
	n=24	n=12	n=12	
Age (years)	46 (37, 52)	50 (43, 52)	45 (31, 53)	0.370
Gender, women	16.7	0	25	0.093
Race, non-white	83.3	91.7	75.0	0.590
Time prior to ECMO				
initiation (days)	5 (2, 7)	6 (3, 8)	5 (2, 6)	0.400
MA (mm)	72.8 (71.2, 78.4)	74.9 (72.3, 79.9)	72.1 (70.6, 77.9)	0.225
R time (min)	10.4 (8.5, 12.8)	11.6 (8.6, 12.5)	10.3 (8.4, 13.1)	0.864
D-dimer (ug/mL)	3.5 (2.4, 7.9)	3.1 (2.4, 4.6)	3.9 (2.5, 9.0)	0.312
Fibrinogen (mg/dL)	543.5 (476.5, 674.6)	582.5 (538.4, 758.4)	501.5 (447.5, 575.9)	0.043
CRP (mg/dL)	11.1 (4.8, 17.8)	15.3 (8.4, 26.9)	7.55 (3.2, 12.3)	0.038
Ferritin (ng/mL)	985.2 (631.0, 2047.9)	1004.6 (577.8, 2258.3)	965.8 (730.7, 1785.0)	0.922
Bleeding complication	8.3	16.7	0	0.478
Time on ECMO (days)	13 (9, 20)	16 (12, 20)	10 (8, 16)	0.111
Death during				

Data presented as median (25th percentile, 75th percentile) or n (%) unless otherwise indicated ECMO, extracorporeal membrane oxygenation; MA, maximum amplitude; CRP, C-reactive protein

33.3

8.3

0.317

20.8

All patients studied received therapeutic anticoagulation per institutional ECMO protocol with occasional cross-over between specific anticoagulant. Forty-six TEGs were obtained on heparin while 122 TEGs were obtained on bivalirudin. Matching D-dimer values were available for all TEGs and there were 7 instances where matching fibrinogen values were not obtained.

D-dimer was examined as a possible predictor of MA in patients on heparin, on bivalirudin, and in aggregate. D-dimer was found to be significantly negatively correlated with MA in all three analyses (p=0.001, <0.001, and <0.001 respectively) (Fig 1A). D-dimer explained little of the variance in MA values (adjusted R²=0.221, 0.112, and 0.162 respectively). Fibrinogen was found

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

to be positively correlated with MA. Ln(fibringen) explained over 50% of the variance in ln(MA) (adjusted $R^2 = 0.567$) and the association was significant for patients on heparin, bivalirudin, and in aggregate (p < 0.001) (Fig 1B). With ln(fibringen) in the model, CRP and ferritin were examined as additional predictors and were not significant. Fig 1. Linear regression model. (A) Ln(MA) vs. ln(D-dimer) with linear regression for patients on heparin, bivalirudin, and aggregated patients. (B) Ln(MA) vs. ln(fibrinogen) with linear regression for patients on heparin, bivalirudin, and aggregated patients. All TEG MA values were then categorized as ≥ 68 mm and < 68 mm. MA values ≥ 68 mm were associated with lower absolute D-dimer values and higher absolute fibringen values (p<0.001). Receiver operator curves (ROC) based on CRP (Fig 2) and fibrinogen levels (Fig 3) were estimated. CRP accuracy in classifying MA \geq 68 mm was poor (AUC 0.707 CI: 0.606-0.807) while classification accuracy of fibrinogen for a MA \geq 68 mm was excellent (AUC 0.934 CI: 0.883-0.984). AUC was greater for the ROC curve utilizing fibringen as a predictor (p<0.001). A fibringen cutoff of 441 mg/dL to predict MA \geq 68 mm (sensitivity of 91.2%, specificity 85.7%) satisfies the closest-to-(0, 1) criterion for threshold selection. Fig 2. ROC curve for C-reactive protein as a predictor of MA \geq 68 mm. Fig 3. ROC curve for fibrinogen as a predictor of MA \geq 68 mm. **Discussion** The emergence of COVID-19 as a global pandemic has necessitated the implementation of treatment protocols based on expert opinion given limited available clinical data. D-dimer has been cited as correlating with worse clinical outcomes in COVID-19 and coagulopathy has been

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

noted to be a common feature of severe infection.[3-5, 10] However, absolute magnitude of Ddimer has not been convincingly demonstrated to be linked to an increased risk of small or large vessel thrombosis in this disease.[2] In this present study we aimed to evaluate the correlation of commonly available measures of coagulopathy (D-dimer and fibrinogen) with a validated reference standard (TEG). TEG MA values have previously been demonstrated to correlate with degree of hypercoagulability in a wide number of clinical conditions.[13] Our results demonstrate that in this population of critically ill COVID-19 patients receiving ECMO therapy, absolute D-dimer magnitude did not correlate positively with degree of hypercoagulability as measured by TEG MA. On the contrary; D-dimer concentration was actually inversely related to MA in our study population. This finding was unexpected and the physiologic basis is uncertain. A number of national guidelines have been published regarding the management of COVID-19 coagulopathy. These guidelines, in our view, are appropriately conservative with respect to recommendations related to the use of therapeutic dosing of anticoagulants for the management of critically ill patients with COVID-19.[2, 3, 15] Despite these guidelines, local and regional hospital practices vary widely, with some recommending D-dimer thresholds to aid the decision regarding initiation and intensity of anticoagulation. Based on our data, we speculate that commonly noted severe D-dimer aberrations are likely markers of COVID-19 related sepsis rather than degree of hypercoagulability. In the absence of additional data, it seems prudent to abandon the practice of D-dimer based thresholds to aid in the decision regarding the initiation of anticoagulation in COVID-19.

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

Studies have noted a clear association between fibrinogen and MA values in other clinical conditions.[14] Marked derangements in fibrinogen has been noted to be common in COVID-19 and an analysis of patients with COVID-19 not receiving ECMO and studied at entry into the ICU also demonstrated an association between MA and fibringen.[10, 16] In this study, fibringen levels were independent predictors of clot strength among patient with other signs of hypercoagulable status.[16] We found fibringen to be a much better predictor of magnitude of MA than D-dimer. In our population a fibrinogen of greater than 441 mg/dL had sensitivity of 91.2% and specificity 85.7% for detection of MA \geq 68 mm. This finding is of interest given that TEG is not routinely available at many centers and takes specialized training to perform to achieve accurate results. Fibrinogen is a commonly available laboratory tests in most hospital environments and results may be easier to obtain. Thus, it may represent a more practical method for the identification of patients at risk for COVID-19 related hypercoagulability. A new viscoelastic device, the VCM (not yet available in the US but certified in Europe), may offer point-of-care bedside thromboelastograph results which may be useful, especially in austere environments, where fibringen testing is not easily available.[17] Other investigators have compared hemostatic changes in COVID-19 to those noted in disseminated intravascular coagulation (DIC) related to sepsis. Unlike DIC; fibringen clotting activity in COVID-19 is frequently elevated. Further, coagulation factors such as prothrombin time and activated partial thromboplastin time do not follow the typical pattern usually seen with DIC related consumptive coagulopathy. [18] The physiologic basic of the hypercoagulable state noted in patients with COVID 19 is not well proven. We postulate that an imbalance between procoagulant factors and anticoagulant factors is logical. How elements such as factor VIII,

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

antithrombin, von Willebrand factor, and others explain the observed hypercoagulability has yet to be fully elucidated. Our findings should be interpreted in the context of the study limitations. First, our data is retrospectively derived from a single tertiary care center. The study was limited to severe COVID-19 infection requiring ECMO support to facilitate data collection due to the institutional use of TEG as part of the standard care of these patients. Alterations in platelet function is a known phenomenon in patients on ECMO and the implications of this alteration may affect TEG, inflammatory, and coagulation parameters.[19] Microvesicles are particles derived from platelets or monocytes and carry procoagulant activity. Microvesicles have been associated with VTE and have also been noted in patients on ECMO.[20] The interplay between COVID-19 disease and the effects of ECMO may also increase the risk of thromboembolism in these patients. Given these considerations, our selected population may limit generalizability and our findings should be validated in a non-ECMO cohort. Second, all patients in our study were on therapeutic anticoagulation with either heparin or bivalirudin per standard institutional ECMO protocol. Deviation from protocolized dosing of therapeutic anticoagulation was occasionally noted. Several of the patients in this report experienced clotting at cannulation sites despite boluses of heparin and one patient received tissue plasminogen activator in addition to anticoagulation for repetitive pulmonary emboli. There is limited data regarding the use of bivalirudin in patients with COVID-19 on ECMO and further investigation of direct thrombin inhibitors versus traditional heparin anticoagulation is needed. The role of antiplatelet agents should also be explored further in this population. As a result, the effects of anticoagulation and dosing adjustments of these medications on the study outcomes are unknown and may introduce

a source of bias. Of note, all findings were consistent when examined for patients on heparin

Conclusion

In critically ill patients with COVID-19, D-dimer appears to have an inverse relationship with degree of hypercoagulability as measured by TEG MA. D-dimer elevation may reflect severity of COVID-19 related sepsis rather than designate patients likely to benefit from anticoagulation. Fibrinogen concentration may represent a more useful marker of hypercoagulability in this population and further study is warranted.

Acknowledgments

We would like to thank all physicians, nurses, respiratory therapists, perfusionists, pharmacists, and ancillary care services who have tirelessly provided care for patients with COVID-19 within the Inova health system.

287

- 1. Iba, T., et al., Coagulopathy of Coronavirus Disease 2019. Crit Care Med, 2020.
- 289 2. Moores, L.K., et al., *Prevention, diagnosis and treatment of venous thromboembolism in patients with COVID-19: CHEST Guideline and Expert Panel Report.* Chest, 2020.
- 291 3. Connors, J.M. and J.H. Levy, *COVID-19 and its implications for thrombosis and anticoagulation*. Blood, 2020. **135**(23): p. 2033-2040.
- 4. Ackermann, M., et al., *Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19.* N Engl J Med, 2020.
- Magro, C., et al., Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl Res, 2020.
 220: p. 1-13.
- Oudkerk, M., et al., Diagnosis, Prevention, and Treatment of Thromboembolic
 Complications in COVID-19: Report of the National Institute for Public Health of the
 Netherlands. Radiology, 2020: p. 201629.
- 7. Casini, A., et al., Thromboprophylaxis and laboratory monitoring for in-hospital patients with COVID-19 a Swiss consensus statement by the Working Party Hemostasis. Swiss Med Wkly, 2020. **150**: p. w20247.
- 8. Paranjpe, I., et al., Association of Treatment Dose Anticoagulation with In-Hospital Survival Among Hospitalized Patients with COVID-19. J Am Coll Cardiol, 2020.
- Shah, K., et al., *Magnitude of D-dimer matters for diagnosing pulmonary embolus*. Am J Emerg Med, 2013. **31**(6): p. 942-5.
- Tang, N., et al., *Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.* J Thromb Haemost, 2020. **18**(4): p. 844-847.
- 310 11. Adam, S.S., N.S. Key, and C.S. Greenberg, *D-dimer antigen: current concepts and future* 311 prospects. Blood, 2009. **113**(13): p. 2878-87.
- 312 12. Schutte, T., A. Thijs, and Y.M. Smulders, *Never ignore extremely elevated D-dimer* 1313 14. Schutte, T., A. Thijs, and Y.M. Smulders, *Never ignore extremely elevated D-dimer* 1313 15. levels: they are specific for serious illness. Neth J Med, 2016. **74**(10): p. 443-448.
- 314 13. Brown, W., et al., *Ability of Thromboelastography to Detect Hypercoagulability: A Systematic Review and Meta-Analysis.* J Orthop Trauma, 2020. **34**(6): p. 278-286.
- 316 14. Kupcinskiene, K., et al., *Monitoring of Hypercoagulability by Thromboelastography in Bariatric Surgery*. Med Sci Monit, 2017. **23**: p. 1819-1826.
- 318 15. Barnes, G., A. Cuker, and T. Gluckman, *Thrombosis and COVID-19: FAQs For Current Practice*. 2020.
- Yuriditsky, E., et al., Thromboelastography Profiles of Critically Ill Patients With
 Coronavirus Disease 2019. Crit Care Med, 2020.
- 322 17. Brearton, C., et al., Performance Evaluation of a New Point of Care Viscoelastic 323 Coagulation Monitoring System in Major Abdominal, Orthopaedic and Vascular

324 *Surgery*. Platelets, 2020: p. 1-8.

- Panigada, M., et al., *Hypercoagulability of COVID-19 patients in intensive care unit: A* report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost, 2020. **18**(7): p. 1738-1742.
- Balle, C.M., et al., Platelet Function During Extracorporeal Membrane Oxygenation in
 Adult Patients. Front Cardiovasc Med, 2019. 6: p. 114.
- 330 20. Meyer, A.D., et al., *Platelet-derived microparticles generated by neonatal extracorporeal membrane oxygenation systems.* ASAIO J, 2015. **61**(1): p. 37-42.

